<code id='9665FFFAD3'></code><style id='9665FFFAD3'></style>
    • <acronym id='9665FFFAD3'></acronym>
      <center id='9665FFFAD3'><center id='9665FFFAD3'><tfoot id='9665FFFAD3'></tfoot></center><abbr id='9665FFFAD3'><dir id='9665FFFAD3'><tfoot id='9665FFFAD3'></tfoot><noframes id='9665FFFAD3'>

    • <optgroup id='9665FFFAD3'><strike id='9665FFFAD3'><sup id='9665FFFAD3'></sup></strike><code id='9665FFFAD3'></code></optgroup>
        1. <b id='9665FFFAD3'><label id='9665FFFAD3'><select id='9665FFFAD3'><dt id='9665FFFAD3'><span id='9665FFFAD3'></span></dt></select></label></b><u id='9665FFFAD3'></u>
          <i id='9665FFFAD3'><strike id='9665FFFAD3'><tt id='9665FFFAD3'><pre id='9665FFFAD3'></pre></tt></strike></i>

          Home / explore / explore

          explore


          explore

          author:focus    Page View:914
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In